However, especially in dogs, dexmedetomidine has undesirable cardiovascular effects characterized by marked vasoconstriction and consequent reductions in heart rate, followed by decreases in the cardiac index and tissue oxygen delivery (Pypendop & Verstegen, 1998) . This effect is mediated by α 2 -adrenoceptors located on vascular smooth muscle cells (Bloor et al., 1992b; Flacke et al., 1990 Flacke et al., & 1993 Link et al., 1996) . In humans, the adverse cardiovascular effects are commonly not very pronounced, probably due to more conservative dosing regimens and a possibly smaller sensitivity of humans than dogs to the peripheral vasoconstrictive effects of dexmedetomidine. However, also humans show these typical α 2 -adrenoceptor agonist-mediated vasoactive effects, especially when higher than therapeutically recommended plasma concentrations are reached (Bloor et al., 1992a; Ebert et al., 2000; Snapir et al., 2006) . Dexmedetomidine has also been shown to dose-dependently reduce its own clearance in humans, a phenomenon mediated via reduced cardiac output (Dutta et al., 2000) . Similarly, dexmedetomidine has been suggested to alter its own pharmacokinetics in dogs (Salonen et al., 1995; Kuusela et al., 2000) . It also reduces the distribution of thiopental in humans (Buhrer et al., 1994) .
MK-467 (also known as L-659,066) (2R-trans)-N-(2-)1,3,4,7,12b-hexahydro-2'-oxospiro(2H-benzofuro,(2,3-a)quinolizine-2,4'-imidazolidin-3'-yl)ethyl methanesulphonamide) was first introduced by Clineschmidt et al. (1988) as a peripherally acting α 2 -adrenoceptor antagonist that did not prevent
dexmedetomidine-induced sedation in rats (Doze et al., 1989) . It has since been shown to be capable of attenuating or preventing the initial vasoconstriction and the consequent hemodynamic disturbances induced by dexmedetomidine in dogs (Pagel et al., 1998; Enouri et al., 2008; Honkavaara et al., 2008 Honkavaara et al., & 2011 and sheep (Bryant et al., 1998; Raekallio et al., 2010) while preserving the centrally mediated desired effects (Honkavaara et al., 2008; Restitutti et al., 2011 Hemodynamic data and assessments of the central nervous system effects were also recorded for separate analysis and reporting (Honkavaara et al., 2011; Restitutti et al., 2011) .
Study protocol. Each dog was treated five times using a randomized cross-over design with wash-out periods of 14 days between the treatments. The treatments were as follows: dexmedetomidine (Dexdomitor® 0.5 mg/ml, Orion Pharma, Turku, were probably caused by this decrease in plasma dexmedetomidine concentrations.
Large variation was observed between the dogs in early plasma concentrations and
This article has not been copyedited and formatted. The final version may differ from this version. There were no statistically significant differences in the calculated T 1/2β of dexmedetomidine between the treatments. This might suggest that after the initial distribution phase, the drug's rate of elimination was relatively independent of organ perfusion (e.g. hepatic perfusion that was probably reduced after dexmedetomidine alone). However, in dogs anesthetized with either chloralose/urethane or fentanyl/halothane, only a moderate reduction in blood flow through the hepatic artery was observed after administration of increasing doses (up to 10 µg/kg) of dexmedetomidine (Lawrence et al., 1996) . While organ-specific perfusion measurements were not performed in this study, it could be expected that the ratelimiting step in the elimination of dexmedetomidine is more dependent on the metabolism of the parent compound than liver blood flow. In previous studies investigating the metabolism of racemic medetomidine, the importance of biotransformation on the terminal clearance rate in dogs has been highlighted (Salonen et al., 1989) . Furthermore, in an in vitro study, Kaivosaari et al. (2002) postulated that canine hepatocytes produce the glucuronide conjugate of dexmedetomidine at a much slower rate than human hepatocytes. These findings treatments in the present study. However, the hemodynamic differences between treatments in the present study cannot be ignored, either. Hepatic clearance can be influenced not only by the capacity of hepatocytes to eliminate a drug from the blood stream but also by drug delivery regulated by liver blood flow (Wilkinson, 1987) . For example, in dogs, reductions in cardiac output and liver blood flow induced by propranolol markedly reduced the clearance of lidocaine without affecting its hepatic extraction ratio (Branch et al., 1973) . Consequently, after a reduction in liver perfusion, total hepatic clearance would remain unaffected only if the rate of elimination was independent of drug delivery to the hepatocytes via blood flow (Nies et al, 1974) . While Lawrence et al. (1996) 
